Comparison of Efficacy of Bromocriptine mesylate and Pioglitazone in Type 2 Diabetes Patients: A Randomized open labeled Controlled clinical trial. - NI

Smt Kashibai Navale Medical College and Hospital0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Age between 30 to 70 years
•Sex: Male or Non-lactating female
•HbA1 more than 8
•Type 2 Diabetic patient on Sulphonylureas or Metformin not responding adequately

•Age less than 30 yrs.
•Lactating mother
•Patient with Insulin dependent Diabetes Mellites
•Patient who is taking oral antidiabetic drugs other than Sulphonyureas and Metformin
•Severe and Complicated diabetes
•Patient with IHD
•Patients having renal or hepatic dysfunction
•Patient of Parkinsonism, syncopal migraine
•Patient who is taking Salicylates, Sulfonamides, Chloramphenicol, Probenecid, Phenithiazines, Butyrophenones, Thioxanthenes,Metoclopramide
•Strong Inhibitors/Inducers/ Substrates of CYP 3A4
•Inhibitors -sodium valproate, erythromycin, Fluroquinolones except ofloxacin, verapamil, diltiazem, propoxyphene, allopurinol, MAO inhibitors, disulfiram, tolbutamide, metronidazole,captopril, enalpril, carbidopa
•Inducers :Phenobarbitone, phenytoin, carbamazepine, ethanol, clofibrate, griseofulvin, Rifampcin, pyridoxine
•Substrates: barbiturates, warfarin,theophylline, paracetamol, ascorbic acid, dextropropoxyphene, tolbutamide, diazepam, vit D, oral contraceptives, antidepressants, quinidine, terfanidine,phenytion, carbamazepine, morphine, pethidine,
•HIV positive patients

发起方

Smt Kashibai Navale Medical College and Hospital